"Da" Benefits All, "Pulse" Travels Bashu: Qu County People's Hospital in Dazhou Among Nation's First to Perform XuanYu RhythPulse® PFA Ablation
ShineyoMedical
Provider of Atrial Fibrillation Electrophysiology and Peripheral Vascular Intervention Solutions
Click the blue words to follow us
ENTERPRISE
In the radiant autumn light, with fruitful branches laden with harvest, on September 26, 2025, Director Wang Xiaoqu and his team from the Cardiology Department of Qu County People's Hospital in Dazhou City successfully completed a case using RhythPulse, a product produced by ShineyoMedical in China.®-PFA Pulsed Electric Field Ablation Surgery.
In the context of rapid advancements in medical technology, Qu County People's Hospital consistently upholds the principle of "patient-centered care," continuously striving for excellence and actively introducing cutting-edge medical technologies. Recently, the hospital announced good news as one of the first institutions in China to implement ShineyoMedical's RhythPulse.®-PFA Pulse Ablation Surgery Brings New Hope to Patients with Atrial Fibrillation.
Patient Basic Information
Patient's admission diagnosis: Coronary atherosclerotic heart disease, hypertension, persistent atrial fibrillation
Ultrasound Diagnosis Report: Left Atrial Anteroposterior Diameter 46mm, EF 66%
Surgical Procedure
The surgery was performed under local anesthesia. After routine vascular puncture, the atrial septal puncture sheath was advanced through the inferior vena cava to the right atrium, and the atrial septum was punctured (anterior and inferior) to reach the left atrium. ShineyoMedical's RhythPulse was used.® A 10mm catheter was used for left atrial modeling and substrate mapping with the support of a three-dimensional system.
During the procedure, a 10mm catheter was used for bilateral PVI + posterior wall box. A total of 53 sets of ablations were performed in the left atrium (5 applications per set). After electrical cardioversion, the rhythm converted to atrial flutter, followed by voltage mapping in the right atrium. Mapping revealed the ablation target at the cavotricuspid isthmus. After delivering 3 sets of ablations (5 applications per set) at the cavotricuspid isthmus, the rhythm converted to sinus rhythm.
Surgical Highlights
1、Shorten Operation Time:The surgery took only 60 minutes, nearly an hour shorter than traditional radiofrequency ablation procedures;
2、Multiple Models, Multiple Choices:Offering ablation catheters with various diameters ranging from 10-25mm, providing more options during procedures;
3、3D Precision Positioning:Compatible with mainstream 3D systems for precise targeted ablation, improving success rates.
Expert Profile
Wan Yun
Attending Physician at Qu County People's Hospital
With many years of clinical experience, proficient in the diagnosis and treatment of common internal medicine diseases such as hypertension, diabetes, stroke, and COPD, especially skilled in the diagnosis and treatment of cardiovascular system diseases such as coronary heart disease, angina pectoris, myocardial infarction, heart failure, and arrhythmia.
END
【ShineyoMedical RhythPulse®-PFA System】
ShineyoMedical's RhythPulse®-PFA System is the first approved Pulse Field Ablation (PFA) system in China that integrates multi-channel, large focal, and targeted ablation, primarily used for treating rapid arrhythmias such as drug-refractory and recurrent atrial fibrillation. Its core advantages include:
Large Focal Spot Design:Using the world's first 10mm ring ablation catheter, a single discharge can cover a lesion area with a diameter of 10mm, increasing the ablation efficiency by more than three times compared to traditional technology.
Targeted Ablation Technology:Equipped with an intelligent proximity detection module, it monitors the contact status between the electrode and myocardial tissue in real time, reducing the risk of hemolysis caused by ineffective discharges, and decreasing postoperative plasma free hemoglobin content by 50%.
Excellent clinical validation:In the clinical trial of 151 cases, the immediate success rate was 100%, and the success rate of atrial fibrillation treatment at 12 months post-operation reached 85.07%, achieving an internationally leading standard.
